Literature DB >> 1458892

Pharmacokinetics of levonorgestrel and ethinylestradiol in 9 women who received a low-dose oral contraceptive over a treatment period of 3 months and, after a wash-out phase, a single oral administration of the same contraceptive formulation.

W Kuhnz1, G al-Yacoub, A Fuhrmeister.   

Abstract

The pharmacokinetics of levonorgestrel (LNG) and ethinylestradiol (EE2) were determined in 9 healthy women (age 23 to 42 years), during a treatment period of three months with a low-dose oral contraceptive, containing 0.15 mg LNG together with 0.03 mg EE2 (Microgynon). After a wash-out period of 3 months, 8 of these women received a single administration of the same formulation. The results showed that there was an increase in serum trough levels of LNG, reaching steady-state in the second half of each treatment cycle. The LNG levels achieved were about 3 to 4 times higher than anticipated on the basis of single dose administration. At the end of treatment cycles one and three, the terminal half-life of LNG was in the range of 24-26 h, while a mean value of 20 h was observed following single dose administration. An EE2-induced increase in the SHBG concentration of about 50% as compared to pretreatment values was observed during a treatment cycle. Pretreatment values were reached following the drug-free interval of 7 days between two cycles. After single dose administration, the free fraction of LNG was 1.3 +/- 0.2% and the fractions bound to SHBG and albumin were 64.1 +/- 4.2% and 34.6 +/- 4.0%, respectively. Serum protein binding of LNG did not change during chronic treatment. An about 50% reduction in total and unbound clearance of LNG was observed during chronic treatment, as compared to single dose administration. Increased SHBG binding capacity and a reduced hepatic metabolic capacity were discussed as possible causes of accumulating LNG concentrations in the serum. On the last day of treatment cycles one and three, the AUC(0-24h) values of EE2 were 728 +/- 314 and 778 +/- 318 pg x ml-1 x h, respectively, and were in keeping with data reported from others.

Entities:  

Keywords:  Biology; Clinical Research; Contraception; Contraceptive Agents, Estrogen--prevention and control; Contraceptive Agents, Female--pharmacodynamics; Contraceptive Agents, Female--prevention and control; Contraceptive Agents, Progestin--prevention and control; Contraceptive Agents--pharmacodynamics; Contraceptive Agents--prevention and control; Contraceptive Methods; Developed Countries; Ethinyl Estradiol--prevention and control; Europe; Examinations And Diagnoses; Family Planning; Germany; Hematologic Tests; Hematological Effects; Hemic System; Hepatic Effects; Laboratory Examinations And Diagnoses; Laboratory Procedures; Levonorgestrel--pharmacodynamics; Oral Contraceptives; Oral Contraceptives, Combined; Physiology; Plasma Protein Binding Capacity; Research Methodology; Research Report; Serum Protein Effects; Western Europe

Mesh:

Substances:

Year:  1992        PMID: 1458892     DOI: 10.1016/0010-7824(92)90149-n

Source DB:  PubMed          Journal:  Contraception        ISSN: 0010-7824            Impact factor:   3.375


  11 in total

1.  Cutaneous postural vasoconstriction is modified by exogenous but not endogenous female hormones in young women.

Authors:  Gemma D Bishop; Margaret D Brown
Journal:  Clin Auton Res       Date:  2007-01-30       Impact factor: 4.435

Review 2.  A risk-benefit assessment of the levonorgestrel-releasing intrauterine system.

Authors:  F Sturridge; J Guillebaud
Journal:  Drug Saf       Date:  1996-12       Impact factor: 5.606

Review 3.  Perspectives on variability in pharmacokinetics of an oral contraceptive product.

Authors:  William J Jusko
Journal:  Contraception       Date:  2016-07-27       Impact factor: 3.375

Review 4.  Levonorgestrel. Clinical pharmacokinetics.

Authors:  K Fotherby
Journal:  Clin Pharmacokinet       Date:  1995-03       Impact factor: 6.447

5.  Effect of a combined estrogen and progesterone oral contraceptive on circulating adipocytokines adiponectin, resistin and DLK-1 in normal and obese female rhesus monkeys.

Authors:  Kate A Shaw; Jon D Hennebold; Alison B Edelman
Journal:  Contraception       Date:  2012-12-04       Impact factor: 3.375

Review 6.  Clarification of contraceptive drug pharmacokinetics in obesity.

Authors:  William J Jusko
Journal:  Contraception       Date:  2016-08-16       Impact factor: 3.375

Review 7.  Pharmacokinetics, metabolism and serum concentrations of progestins used in contraception.

Authors:  Alexis J Bick; Renate Louw-du Toit; Salndave B Skosana; Donita Africander; Janet P Hapgood
Journal:  Pharmacol Ther       Date:  2020-12-13       Impact factor: 13.400

8.  Pharmacokinetics of Oral Levonorgestrel in Women After Roux-en-Y Gastric Bypass Surgery and in BMI-Matched Controls.

Authors:  Charlotte Ginstman; Helena Kopp Kallner; Johanna Fagerberg-Silwer; Björn Carlsson; Andreas Ärlemalm; Ylva Böttiger; Jan Brynhildsen
Journal:  Obes Surg       Date:  2020-06       Impact factor: 4.129

9.  Efficacy of combined contraceptive vaginal ring versus oral contraceptive pills in achieving hypothalamic-pituitary-ovarian axis suppression in egg donor in vitro fertilization cycles.

Authors:  Robin Lynn Thomas; Lisa Marie Halvorson; Bruce Richard Carr; Kathleen Marie Doody; Kevin John Doody
Journal:  J Reprod Infertil       Date:  2013-10

10.  Evaluation of the Effect of Tofacitinib on the Pharmacokinetics of Oral Contraceptive Steroids in Healthy Female Volunteers.

Authors:  Sujatha Menon; Richard Riese; Ronnie Wang; Christine W Alvey; Haihong Shi; Wendy Petit; Sriram Krishnaswami
Journal:  Clin Pharmacol Drug Dev       Date:  2016-06-26
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.